GlobeImmune, Inc., today announced that initial survival data from GI-4000-02, a Phase 2b study of the company’s lead cancer product candidate, GI-4000, in subjects with resected pancreas cancer, have been accepted for oral presentation at the European Society for Medical … Continue reading
LOUISVILLE, Colo., November 3, 2010 – GlobeImmune Inc. today announced that the company has been awarded three grants totaling $733,438 under the federal Therapeutic Discovery Project Program. GlobeImmune will receive grant money for each of the following clinical-stage therapeutic vaccine … Continue reading
Additional data suggest that cellular immunity may be a fundamental deficit in hardest-to-treat IL28B T/T genotype patients and is corrected by GI-5005 Data to be presented at annual meeting of the American Association for the Study of the Liver Disease … Continue reading
LOUISVILLE, Colo., October 28, 2010 – GlobeImmune Inc. today announced the expansion of its Phase 2b clinical trial of GI-5005, an investigational Tarmogen product for the treatment of hepatitis C virus (HCV) infection. The Company previously reported data demonstrating a … Continue reading
Immunology data also to be presented in poster session LOUISVILLE, Colo., October 1, 2010 – GlobeImmune Inc. today announced that an abstract related to GI-5005, its Phase 2 investigational hepatitis C virus (HCV) product candidate, has been accepted for a … Continue reading
Data Showing Correlation of GI-5005 Therapeutic Vaccine Treatment Response and IL-28 B Genotype Presented at 45th Annual Meeting of the European Association for the Study of the Liver LOUISVILLE, Colo., April 19, 2010 – GlobeImmune Inc. announced Phase 2b data … Continue reading
Final Phase 2b Data for GI-5005 in Treatment-naïve Patients Presented at 45th Annual Meeting of the European Association for the Study of the Liver LOUISVILLE, Colo., April 15, 2010 – GlobeImmune, Inc. today announced final Phase 2b data for GI-5005, … Continue reading
Sustained Virologic Response, Pharmacogenomic and Biopsy Analysis of HCV Patients Receiving GI-5005 Therapeutic Vaccine to be Presented at the Annual Meeting of the European Association for the Study of the Liver LOUISVILLE, Colo., March 17, 2010 – GlobeImmune Inc. today … Continue reading
LOUISVILLE, CO, January 19, 2010 – GlobeImmune Inc., a company developing novel therapies for patients with cancer and infectious diseases, today announced a Series E Preferred Stock financing of $17.5 million. The round was led by new investors Generali Financial … Continue reading
Phase 2b Data Presented at American Association for the Study of Liver Diseases Meeting LOUISVILLE, Colo., Nov. 2, 2009 – GlobeImmune Inc. will present Phase 2b data today at the 60th Annual Meeting of the American Association for the Study … Continue reading